Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DermAtOmics-II
2023-506165-62-00Phase 4Authorised
- Sponsor
- Hospital Universitario La Paz
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of abrocitinib, baricitinib, dupilumab, upadacitinib, tralokinumab and 1 more in atopic dermatitis (AD) (2 cohorts), sponsored by Hospital Universitario La Paz. Primary endpoint: Primary non-response rate at week 16. Planned start Aug 2023; status: authorised.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-506165-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506165-62-00.